Fredun Pharmaceuticals Reports Strong Growth and Plans NSE Listing

Net Profit: Rs 18.57 crore (up 96.9% YoY) | Revenue: Rs 267.64 crore (up 84.2% YoY)

Reader Takeaway: Strong operational momentum driven by sharp profit growth is coupled with potential stock liquidity via NSE listing.

What just happened

Fredun Pharmaceuticals has announced impressive financial results for the quarter ended September 30, 2026. Simultaneously, the company board has officially cleared the proposal to list its equity shares on the National Stock Exchange (NSE), moving beyond its current trading status. This decision remains subject to regulatory clearances and compliance with exchange norms.

Why this matters

A listing on the NSE typically provides higher liquidity and greater visibility for shareholders compared to a singular exchange listing. For retail investors, the substantial jump in revenue from Rs 145.29 crore to Rs 267.64 crore indicates the company is scaling operations effectively within the pharmaceutical sector.

Auditor Status

The statutory auditor, M/s. R.H. Nisar & Co., has issued an unmodified review report for the quarter. This indicates that the company's financial statements are in compliance with relevant accounting standards and listing regulations, providing a clean bill of health for the reported figures.

Context Metrics

The company’s net profit nearly doubled, rising to Rs 18.57 crore from Rs 9.43 crore in the corresponding period of the previous year. This reflects a robust growth trajectory as the firm executes its expansion strategy.

What to track next

Investors should monitor the formal submission and timeline of the application to the NSE. Any further regulatory updates or disclosures regarding the listing process will be the primary catalyst for market sentiment regarding the stock’s accessibility.